Bisphosphonates (BPs) are an important class of drugs, useful in the treatment of some metabolic and oncologic skeletal diseases. BPs have shown a sure effectiveness in the treatment and in the palliative care of such pathologies; on the other hand, an avascular osteonecrosis of the jaws (B-ONJ = Bisphosphonate OsteoNecrosis of the Jaw) has recently been reported as an adverse effect not only of BP intravenous infusions, but also of their prolonged oral administration. B-ONJ normally follows a dental extraction or other surgical procedure in the oral cavity, but it also can develop spontaneously. In the latter case, some systemic risk factors, such as comorbidities and co-therapies or jaw anatomical conditions, can play a leading role in the onset of this pathologic condition. B-ONJ is an uncommon but potentially serious complication of BP therapy that can gravely affect the patient's quality of life, producing significant morbidity. To date, no therapies are completely effective and predictable in the treatment of B-ONJ, therefore prevention should be strongly promoted by sharing knowledge in the involved medical community.

BISPHOSPHONATE AND OSTEONECROSIS OF THE JAW: THE ORAL SURGEON'S PERSPECTIVE / Pompa, Giorgio; I., Bignozzi; Cristalli, MARIA PAOLA; A., Quaranta; DI CARLO, Stefano; Annibali, Susanna. - In: EUROPEAN JOURNAL OF INFLAMMATION. - ISSN 1721-727X. - ELETTRONICO. - 10:1(2012), pp. 11-23.

BISPHOSPHONATE AND OSTEONECROSIS OF THE JAW: THE ORAL SURGEON'S PERSPECTIVE

POMPA, Giorgio;CRISTALLI, MARIA PAOLA;DI CARLO, Stefano;ANNIBALI, Susanna
2012

Abstract

Bisphosphonates (BPs) are an important class of drugs, useful in the treatment of some metabolic and oncologic skeletal diseases. BPs have shown a sure effectiveness in the treatment and in the palliative care of such pathologies; on the other hand, an avascular osteonecrosis of the jaws (B-ONJ = Bisphosphonate OsteoNecrosis of the Jaw) has recently been reported as an adverse effect not only of BP intravenous infusions, but also of their prolonged oral administration. B-ONJ normally follows a dental extraction or other surgical procedure in the oral cavity, but it also can develop spontaneously. In the latter case, some systemic risk factors, such as comorbidities and co-therapies or jaw anatomical conditions, can play a leading role in the onset of this pathologic condition. B-ONJ is an uncommon but potentially serious complication of BP therapy that can gravely affect the patient's quality of life, producing significant morbidity. To date, no therapies are completely effective and predictable in the treatment of B-ONJ, therefore prevention should be strongly promoted by sharing knowledge in the involved medical community.
2012
prevention osteonecrosis of the jaw; pathogenesis; osteonecrosis; jaw bone; risk factors; bisphosphonates; riskfactors
01 Pubblicazione su rivista::01a Articolo in rivista
BISPHOSPHONATE AND OSTEONECROSIS OF THE JAW: THE ORAL SURGEON'S PERSPECTIVE / Pompa, Giorgio; I., Bignozzi; Cristalli, MARIA PAOLA; A., Quaranta; DI CARLO, Stefano; Annibali, Susanna. - In: EUROPEAN JOURNAL OF INFLAMMATION. - ISSN 1721-727X. - ELETTRONICO. - 10:1(2012), pp. 11-23.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/446800
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact